Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cardiovascular phenotype: impact on choice of glucose- lowering therapy.

JPMA. The Journal of the Pakistan Medical Association - 1 Apr 2016

Kalra Sanjay, Gupta Yashdeep, Kishor Kamal

Abstract excerpt

One of the major endpoints to be considered while choosing glucose-lowering therapy is their impact on cardiovascular outcomes. As a corollary, the cardiovascular health assessment of a person with diabetes informs the choice of glucose-lowering treatment. The clinical aspects included in this bidirectional relationship are described in this review as the cardiovascular phenotype. Vital signs, cardiac autonomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzhydryl Compounds
Share to Blood Pressure
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Glucosides

Share to Heart Rate

Share to Hypoglycemic Agents

Share to Metformin

Source

Identifiers

PMID: 27122283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cardiovascular phenotype: impact on choice of glucose- lowering therapy.PMID 27122283Read ↗

When are type 1 diabetic patients at risk for cardiovascular disease?Semantic proximity Read ↗

Phenotyping the Prediabetic Population-A Closer Look at Intermediate Glucose Status and Cardiovascular Disease.Semantic proximity Read ↗

Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes.Semantic proximity Read ↗

Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: Results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortiumSemantic proximity Read ↗

Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetesSemantic proximity Read ↗

Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.Semantic proximity Read ↗

Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetesSemantic proximity Read ↗

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.Semantic proximity Read ↗

The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study.Semantic proximity Read ↗

Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action.Semantic proximity Read ↗

Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.Semantic proximity Read ↗

Effect of Hypoglycemia on Measures of Myocardial Blood Flow and Myocardial Injury in Adults With and Without Type 1 Diabetes: A Prospective, Randomized, Open-Label, Blinded Endpoint, Cross-Over StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.